Gilead Sciences | GILD - Ebit


Gilead Sciences reported $3.85B in EBIT for its fiscal quarter ending in June of 2026.





Ebit Change Date
AbbVie USD 6.88B 156M Sep/2026
Agios Pharmaceuticals USD -110.55M 527K Jun/2026
ALKERMES USD 36.59M 102.52M Sep/2026
Alnylam Pharmaceuticals USD 179.66M 67.06M Sep/2026
Amgen USD 4.68B 65M Sep/2026
Biogen USD 419.5M 663.3M Sep/2026
BioMarin Pharmaceutical USD 205.6M 100M Sep/2026
Bristol-Myers Squibb USD 255M 44M Sep/2026
Coherus Biosciences USD -39.08M 3.65M Dec/2025
Eli Lilly USD 13.09B 635M Sep/2026
Gilead Sciences USD 3.85B 1.17B Jun/2026
GlaxoSmithKline GBP 2.86B 251M Sep/2026
Glaxosmithkline GBP 2.15B 157M Sep/2026
Incyte USD -707.47M 1.41B Sep/2026
J&J USD 6.47B 1B Sep/2026
Merck USD 7.33B 6.49B Sep/2026
Moderna USD -815M 573M Jun/2026
Neurocrine Biosciences USD 343M 123.1M Sep/2026
Novartis USD 5.14B 411M Sep/2026
Pfizer USD 4.85B 5.03B Sep/2026
PTC Therapeutics USD 146.03M 100.14M Jun/2026
Puma Biotechnology USD -2.2M 11.41M Jun/2024
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Sanofi EUR 4.72B 3.6B Sep/2026
Sarepta Therapeutics USD 13.29M 345.14M Jun/2026
United Therapeutics USD 241.3M 134.3M Sep/2026
Vertex Pharmaceuticals USD 1.26B 11.3M Sep/2026